In This Article:
STOCKHOLM, April 23, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) presents clinical data aimed at updating the global haemophilia community attending this year's WFH 2025 Comprehensive Care Summit in Dubai from the 23 – 25 April. New and updated outcomes and analyses will be presented from the XTEND phase 3clinical program testing the effectiveness of Altuvoct® (efanesoctocog alfa) treatment for haemophilia A, including updates on patients' joint health and surgical outcomes in patients.
"At WFH 2025 CCS, Sobi will present highlights from the XTEND phase 3 program and discuss the new treatment paradigm with FVIII levels in the non-haemophilia range. Sharing these clinical outcomes with the wider haemophilia community will help to ensure the latest treatment approaches are widely known and understood," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer at Sobi.
Key data to be presented at WFH 2025 Comprehensive Care Summit, Dubai, UAE
Altuvoct® (efanesoctocog alfa)
|
Oral Presentations | ||
| . | A plain language summary of the association | Oral presentation: Oral FP-TH-02.5 Date: Thursday 24 April 2025 Time: 08:45 – 09:00 Location: Great Ballroom . |
| | Efanesoctocog alfa for the perioperative | Oral presentation: Oral FP-WE-01.5 Time: 16:15 – 16:30 Location: Great Ballroom |
|
Posters | ||
| | SHINE study design: An interventional, open- | Poster presentation: Poster PO-179 Presentation dates and times: Thursday 24 April / 11:00 – 11:30 Poster Networking Event: Thursday 24 |
| | Long-term outcomes of prophylaxis with | Poster presentation. Poster PP-044 Presentation dates and times: Thursday 24 April / 11:00 – 11:30 Poster Networking Event: Thursday 24 |
| | Plain language summary of two-year results | Poster presentation. Poster PP-045 Presentation dates and times: Thursday 24 April / 11:00 – 11:30 |
| | Plain language summary: Efanesoctocog alfa | Poster presentation. Poster PP-046 Presentation dates and times: Thursday 24 April / 11:00 – 11:30 Poster Networking Event: Thursday 24 |
| | The A-MOVE study easily explained: the | Poster presentation: Poster PP-043 Presentation dates and times: Thursday 24 April / 11:00 – 11:30 Poster Networking Event: Thursday 24 |
About efanesoctocog alfa
Efanesoctocog alfa [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] (formerly BIVV001) is a novel and significant part of the week factor VIII therapy. It has the potential to deliver near-normal factor activity levels for significant parts of the week, improving bleed protection in a once-weekly dose for people with haemophilia A. Efanesoctocog alfa builds on the innovative Fc fusion technology by adding a region of von Willebrand factor and XTEN® polypeptides to extend its time in circulation. It is the only therapy that has been shown to break through the von Willebrand factor ceiling, which imposes a half-life limitation on current factor VIII therapies. It was approved as ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] by Sanofi in the US in February 2023.